Ranbaxy Saga - Episode buyout

The story begins (as the story ends for Ranbaxy Laboratories, India’s largest drug manufacturer) the curtains roll down...

When the Singh family sold Ranbaxy Laboratories to Daiichi Sankyo it took everyone by surprise. This deal may well have opened the door for other such transactions in the future. Indian promo ters, who were considered to be sentimentally attached to their businesses, are now analysing their business portfolio and may be willing to cash out at right values. Times they are a-changin’

Never a dull moment these days at Ranbaxy Laboratories, India’s largest drug manufacturer. In the course of the summer, it has resolved its longstanding, much-publicized patent dispute with Pfizer over its generic version of Lipitor, agreed to an imminent buyout by Japanese drugmaker Daiichi Sankyo, and been sued by the U.S. government for alleged data fraud. As Ranbaxy’s World Turns, So Does Generics Model

The Japanese company had agreed in June to pick up 34.8 per cent stake in Ranbaxy, India's largest drug maker, from its promoters, Malvinder Mohan Singh and family. Daiichi Sankyo Company Ltd will pay Rs 737 per share to shareholders of Ranbaxy Laboratories in its open offer beginning Aug 16, the Japanese company said in a regulatory statement here Monday. Daiichi to pay Rs 737 per Ranbaxy share in open offer

More to come...

Be a part of the XTractor community. XTractor is the first of its kind - Literature alert service, that provides manually curated and annotated sentences for the Keywords of user preference. XTractor maps the extracted entities (genes, processes, drugs, diseases etc) to multiple ontologies and enables customized report generation. With XTractor the sentences are categorized into biological significant relationships and it also provides the user with the ability to create his own database for a set of Key terms. Also the user could change the Keywords of preference from time to time, with changing research needs. The categorized sentences could then be tagged and shared across multiple users. Thus XTractor proves to be a platform for getting real-time highly accurate data along with the ability to Share and collaborate.

Sign up it's free, and takes less than a minute. Just click here:www.xtractor.in.

Ranbaxy Laboratories Signs Drug Discovery Development Pact With Merck & Co., Inc.

Life Sciences is the next big thing to IT and that is happening to India now, Ranbaxy to develop anti-infective drugs for Merck...

India's Ranbaxy Laboratories Ltd. (Ranbaxy) is to develop new anti-infective drugs for Merck & Co Inc, (Merck) in a major deal underlining the growing use of Indian pharmaceutical research by multinational Companies.

Ranbaxy and Merck announced today that they have signed a strategic Product Development Agreement (the “Agreement”) providing for a drug discovery and clinical development collaboration for new products, in the anti-infective field. Potential Payments Totaling More than $100 Million .

Ranbaxy and Merck will work together to develop clinically validated anti-bacterial and anti-fungal drug candidates. Ranbaxy will carry-out drug discovery and clinical development through Phase IIa clinical trials, with Merck conducting development and commercialization of drug candidates thereafter.

The Indian group will get an undisclosed upfront sum and could receive more than $100 million for each drug target, depending on successful development and regulatory approval. It will also be entitled to royalties under the five-year deal.